Mind Medicine (MindMed) Inc.
MNMD•NASDAQ•Healthcare•Biotechnology

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Company Information

SectorHealthcare
IndustryBiotechnology
CEORobert Barrow
Founded2019
Employees74
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websitewww.mindmed.co
Phone212 220 6633
Address
One World Trade Center, Suite 8500 New York, New York 10007 United States

Corporate Identifiers

CIK0001813814
CUSIP60255C109
ISINCA60255C8850
SIC2833

Leadership Team & Key Executives

Robert Barrow
Chief Executive Officer and Director
Mark R. Sullivan J.D.
Chief Legal Officer and Corporate Secretary
Dr. Daniel Rollings Karlin M.A., M.D.
Chief Medical Officer
Dr. Scott M. Freeman M.D.
Co-Founder and Clinical Advisor
Leonard Latchman
Co-Founder
Brandi L. Roberts CPA, M.B.A.
Chief Financial Officer
Peter Mack
Senior Vice President of Pharmaceutical Development and Operations
Gitanjali Jain
Vice President and Head of Investor Relations
Beth Calitri
Vice President of Corporate Communications
Stephanie Fagan
Chief Corporate Affairs Officer